NEW YORK, Oct. 18, 2017 /PRNewswire/ -- OTC Markets
Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000
U.S. and global securities, today announced Medicenna Therapeutics
Corp. (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology
company, has qualified to trade on the OTCQX® Best Market.
Medicenna Therapeutics begins trading today on OTCQX under the
symbol "MDNAF." U.S. investors can find current financial
disclosure and Real-Time Level 2 quotes for the company on
www.otcmarkets.com.
"Medicenna Therapeutics joins an impressive roster of Canadian
companies, including more than 25 added this year, that cross-trade
their shares on the OTCQX market to maximize their reach to U.S.
investors. Trading on OTCQX will enable Medicenna to efficiently
broaden accessibility to their news and financial disclosure and
build visibility among U.S. investors," said Jason Paltrowitz, Executive Vice President of
Corporate Services at OTC Markets Group.
"Trading on the OTCQX will improve the Company's ability to
attract a wider audience of investors from both inside and outside
the United States. This corporate
milestone will provide additional visibility within the investment
community enabling us to build awareness more broadly and expand
our current shareholder base in order to drive shareholder value,"
said Elizabeth Williams, Chief
Financial Officer of Medicenna.
Medicenna Therapeutics was sponsored for OTCQX by Burns Figa
& Will PC, a qualified third-party firm responsible for
providing guidance on OTCQX requirements and recommending
membership.
About Medicenna Therapeutics
Medicenna is a clinical
stage immuno-oncology company developing novel highly selective
versions of IL-2, IL-4 and IL-13 Superkines™ and first in class
Empowered Cytokines™ (ECs). Its wholly owned subsidiary,
Houston-based Medicenna BioPharma, is specifically targeting the
Interleukin-4 Receptor (IL4R), which is over-expressed by at least
20 different types of cancer affecting more than one million new
cancer patients every year. Medicenna's lead IL4-EC, MDNA55 is
enrolling patients in a CPRIT (Cancer Prevention and Research
Institute of Texas) funded Phase
2b clinical trial for recurrent glioblastoma (rGBM) at leading
brain cancer centres in the US. MDNA55 has completed 3 clinical
trials in 72 patients, including 66 adults with rGBM, demonstrated
compelling efficacy and obtained Fast-Track and Orphan Drug status
from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs
have the potential to purge both the tumor and the
immunosuppressive tumor microenvironment, offering a unique
treatment paradigm for a large majority of cancer patients.
About OTC Markets Group Inc.
OTC Markets Group Inc.
(OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture
Market, and the Pink® Open Market for 10,000 U.S. and global
securities. Through OTC Link® ATS, we connect a diverse
network of broker-dealers that provide liquidity and execution
services. We enable investors to easily trade through the
broker of their choice and empower companies to improve the quality
of information available for investors.
To learn more about how we create better informed and more
efficient markets, visit www.otcmarkets.com
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC
regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
OTC Markets Group Inc., +1 (212)
896-4428, media@otcmarkets.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-medicenna-therapeutics-to-otcqx-300538345.html
SOURCE OTC Markets Group Inc.